$VNDA News

Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2S

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Vanda Pharmaceuticals Receives Japanese Orphan Drug Designation For Imsidolimab In Generalized Pustular Psoriasis

How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus

Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss

HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

Vanda Pharmaceuticals Q1 Earnings Call Highlights

Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript

Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary

Vanda (VNDA) Q1 2026 Earnings Call Transcript

VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Misses Q1 2026 Estimates as Top-Line Growth Slows

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Vanda Pharmaceuticals' NEREUS Now Commercially Available Throughout U.S. To Prevent Vomiting Induced By Motion In Adults

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

Vanda Pharma Highlights Legislative Proposal Contained In FDA's FY 2027 Congressional Budget Justification; Proposal Will Eliminate Simple Statutory Requirement That FDA Must Review NDA Within 180 Days Of Filing

Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of NEREUS For The Prevention Of Vomiting Induced By GLP-1 Receptor Agonists; Topline Results From Thetis Study Expected By Q4 2026; Phase 2 Study Succeeded And Met Its Primary Endpoint